Transcription Factor AP2   : A Potential Predictor of Chemoresistance in @entity1 With XXXX .

@entity1 @entity5 @entity14 @entity71281 @entity356
UNASSIGNED: Chemotherapy is a mainstay of therapy for advanced @entity356 ( @entity356 ); however, owing to drug resistances, the effectiveness of chemotherapy is not satisfactory for some @entity1 with @entity356 . Therefore, identification of a marker that predicts treatment response is beneficial to @entity1 . Hypermethylation of transcription factor activating enhancer-binding protein 2    ( @entity71281 ) has been implicated in chemotherapy resistance to fluorouracil-based chemotherapy in @entity1 with @entity14 , but its role in @entity356 is still unknown. In this study, we investigated @entity71281 as a predictor of treatment response in @entity356 . We used methylation-sensitive high-resolution melting analysis to study the methylation of @entity71281 in 141 @entity356 tissue specimens and 45 adjacent nontumor tissue specimens. In vitro experiments, we analyzed the expression and methylation of @entity71281 and to examine the sensitivity of @entity356 cell lines to 5-fluorouracil (5-FU). The @entity71281 methylation occurred at a significantly higher incidence rate in @entity5 tissues compared to adjacent nontumor tissues (chi-square [  (2)] = 38.919, P < .001). Hypermethylation of @entity71281 occurred more frequently in @entity5 with lower differentiation grades (P < .001) and was significantly associated with nonresponse to fluorouracil-based chemotherapy (P = .010). Hypermethylation was also associated with decreased expression of @entity71281 (P < .01) and nonresponse to 5-FU exposure in vitro (P < .001). Hypermethylation of @entity71281 was associated with lack of response to fluorouracil-based chemotherapy, indicating that it might be a potential predictor of treatment response in @entity1 with @entity356 .
